A Study to Assess Symptom Burden in Subjects with Nonmyeloid Malignancies Receiving Chemotherapy and Aranesp®

Sponsor ID

20020132

Clinicaltrials.gov ID

NCT00117117

EUCTIS ID

N/A

EudraCT ID

N/A

Study Details

The purpose of this trial is to prospectively assess the relationship between changes in hemoglobin (hgb) and changes in symptom burden associated with anemia in cancer patients receiving chemotherapy supported with Aranesp®.

Additional Study Details

Phase

Phase 4

Product

darbepoetin alfa

Type

Interventional

Masking

None (Open Label)

Enrollment

2423

Additional Study Details

Protocol Summary

Primary Outcome Measures

Not Available

Secondary Outcome Measures

Not Available

Locations

No locations found.